Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TGFα and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Dec 2014

Hobor Sebastijan, Van Emburgh Beth O, Crowley Emily, Misale Sandra, Di Nicolantonio Federica, Bardelli Alberto

Abstract excerpt

PURPOSE: Targeted inhibition of EGFR with the mAbs cetuximab or panitumumab is a valuable treatment for RAS wild-type colorectal cancers. The efficacy of EGFR blockade is limited by the emergence of acquired resistance often attributed to secondary KRAS mutations. Remarkably, tumor biopsies from resistant patients show that only a fraction of the resilient cells carry KRAS mutations. We hypothesized that a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Culture Media, Conditioned

Share to Drug Resistance, Neoplasm

Share to Genes, ras

Share to MAP Kinase Signaling System

Share to Paracrine Communication

Share to Transforming Growth Factor alpha

Source

Identifiers

PMID: 24916700
DOI: 10.1158/1078-0432.CCR-14-0774

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TGFα and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells.PMID 24916700Read ↗

Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models.Semantic proximity Read ↗

Overcoming Resistance to Anti-EGFR Therapy in Colorectal CancerSemantic proximity Read ↗

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.Semantic proximity Read ↗

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.Semantic proximity Read ↗

Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status.Semantic proximity Read ↗

EMT-mediated regulation of CXCL1/5 for resistance to anti-EGFR therapy in colorectal cancer.Semantic proximity Read ↗

Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer.Semantic proximity Read ↗

Stress-induced Rab11a-exosomes induce AREG-mediated cetuximab resistance in colorectal cancerSemantic proximity Read ↗

Upregulation of Sox2 Following Saracatinib Treatment Contributes to a Resistant Phenotype in Colorectal Cancer Cells under Growth Factor-Supplemented Conditions.Semantic proximity Read ↗

Senescence-associated reprogramming induced by interleukin-1 impairs response to EGFR neutralizationSemantic proximity Read ↗

Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer ModelsSemantic proximity Read ↗

Acquisition of anoikis resistance promotes the emergence of oncogenic K-ras mutations in colorectal cancer cells and stimulates their tumorigenicity in vivo.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.